Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)
Part of paid clinical trials in Abbott Park, Illinois.
- Sponsor
- Abbott
- Study ID
- NCT00235885
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- adalimumab — DRUG
Study Details
The purpose of the study is to assess the safety and clinical efficacy of adalimumab in active psoriatic arthritis (PsA) subjects when adalimumab is added to insufficient standard therapy including patients that have failed other TNF therapies
Key Dates
- Start date
- Jul 31, 2005
- Status verified
- Aug 2007
Study Design
- Enrollment
- 445 participants
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
Safety parameters
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Global Medical Information - Abbott | Abbott Park | Illinois | 60064 | - |
Find similar trials in Abbott Park, IL
By condition
By research site
Related Studies
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic MedicinesPHASE3 · Recruiting · Takeda · Chandler, Arizona
- A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic MedicinesPHASE3 · Recruiting · Takeda · Mesa, Arizona
- A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)PHASE4 · Recruiting · Eli Lilly and Company · Avondale, Arizona